Scientist II
Description
Located in Boston and the surrounding communities, Dana-Farber Cancer Institute is a leader in life changing breakthroughs in cancer research and patient care. We are united in our mission of conquering cancer, HIV/AIDS, and related diseases. We strive to create an inclusive, diverse, and equitable environment where we provide compassionate and comprehensive care to patients of all backgrounds, and design programs to promote public health particularly among high-risk and underserved populations. We conduct groundbreaking research that advances treatment, we educate tomorrow's physician/researchers, and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
Overview
Pre-clinical group developing next generation immune effector cellular therapies for cancer is looking for an exceptionally motivated Scientist II to join the team. The position is funded and directly supervised by Dr. Elliott Brea and sits officially within the Belfer Center for Applied Sciences, Barbie Lab and Smith Lab at Dana-Farber Cancer Institute. The group is focused on CAR T cell immunotherapy for cancer and on protein engineering/synthetic biology; taking projects from conception to transgene design/genetic engineering, through reduction to practice, and into in vivo studies, and ultimately to the clinic. The successful candidate will make substantial contributions to advancing our CAR T and TCE programs to the clinic — with a particular focus on TROP2-directed immune effector cell therapy against drug-tolerant persister (DTP) populations in EGFR-mutant non-small cell lung cancer, including CNS/leptomeningeal disease and direct in vivo administration approaches for our candidates.
We expect a strong background in the laboratory methods required to perform this work. Highly relevant experience includes tumor surface antigen target identification and early target biology for CAR T discovery programs; CAR design/engineering and vector engineering; viral vector, DNA, RNA and cell manufacturing at scale for in vitro screening and in vivo studies; CRISPR/Cas9 cell line engineering and target knockdown models; complex 3D and patient-derived solid tumor models; and functional characterization by flow cytometry immunophenotyping, ddPCR, cytokine profiling (ELISA/MSD) and live-cell proliferation and cytotoxicity assays (Incucyte). Experience with in vivo CAR T work and LNP engineering including targeting, is an asset. We provide training to expand the scientist’s toolbox in terms of CAR T cell and cancer immunotherapy workflows. Additional opportunities for growth are attending lectures and journal clubs held here at DFCI and participating in academic and industry collaborations. The work is highly translational and there is a clear path to moving clinical candidates forward based on this work. The applicant will have ample opportunity to design and conduct IND-enabling studies and to work with CROs in support of them.
Primary Duties and Responsibilities
- Demonstrates potential for technical proficiency, scientific creativity, collaboration with others and independent thought.
- Works on problems of moderate to large scope in which analysis of situation or data requires a review of identifiable factors.
- Exercises judgment within defined procedures and practices to determine appropriate action.
- Works under minimal supervision. Wide latitude for independent judgment
- Lead target identification, validation and early target biology efforts for immune effector cell programs, with attention to on-target/off-tumor risk and persistence in solid tumors.
- Engineer and characterize cell line and primary models (CRISPR/Cas9 knockout and knock-in, antigen domain swaps, 3D and patient-derived systems) and manufacture vectors and cells to scale to support in vitro screening and in vivo studies.
Knowledge, Skills and Abilities
- Highly-skilled with extensive proficiency. Works on complex projects related to field.
Minimum Job Qualifications
- Advanced degree preferred.
- Six to nine years experience post undergraduate degree.
- One to two year work experience post education.
- Demonstrated hands-on experience in oncology or immuno-oncology drug discovery, including cell and gene therapy or CAR T approaches.
- Experience partnering with data science, pathology/histology, pre-clinical safety and CRO partners to move programs toward IND.
- Track record of independent experimental design, data interpretation and presentation of findings to scientific stakeholders.
License/Certification/Registration Required: None
Supervisory Responsibilities:
- May assist less-experienced peers.
Patient Contact: None
At Dana-Farber Cancer Institute, we work every day to create an innovative, caring, and inclusive environment where every patient, family, and staff member feels they belong. As relentless as we are in our mission to reduce the burden of cancer for all, we are committed to having faculty and staff who offer multifaceted experiences. Cancer knows no boundaries and when it comes to hiring the most dedicated and compassionate professionals, neither do we. If working in this kind of organization inspires you, we encourage you to apply.
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other characteristics protected by law.
EEO Poster
.Pay Transparency Statement
The hiring range is based on market pay structures, with individual salaries determined by factors such as business needs, market conditions, internal equity, and based on the candidate’s relevant experience, skills and qualifications.
For union positions, the pay range is determined by the Collective Bargaining Agreement (CBA).
$85,000.00 - $104,650.00Skills
Sign in to read and join the discussion.